Engineered Nanoparticles for Drug Delivery in Cancer Therapy
The DOI matches its Crossref record; 579 of the 579 references it cites were found in a registry or an index.
Abstract
In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half‐life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real‐time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next‐generation platform for cancer therapy and many other biomedical applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Vasculature plays an essential role in the growth and metastasis of malignant tumors [103].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
Citations
Cites
Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Chemistry and Properties of Nanocrystals of Different Shapes
Burda, C., Chen, X., Narayanan, R., & El-Sayed, M. A. (2005) · Chemical Reviews · doi:10.1021/cr030063a · Cited by 7,230
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Research works printed but not linked: 29
- Aruna U., 2013, Inter. J. Inn. Pharm. Res., 4, 318
- Langer R., 1998, Nature, 392, 5
- Petre C. E., 2007, Int. J. Nanomed., 2, 277
- Lao J., 2013, J. Drug Delivery, 456409
- Saif M. W., 2007, JOP, 8, 166
- Matsumura Y., 1986, Cancer Res., 46, 6387
- Xu G., 2001, Clin. Cancer Res., 7, 3314
- 10.1016/j.addr.2012.09.008 · doi:10.1016/j.addr.2012.09.008 · Paper page
- Pundir S., 2013, Int. J. Drug Res. Technol., 3, 12
- 10.1021/jp077468 · doi:10.1021/jp077468
- Mohanraj V. J., 2006, J. Pharm. Res., 5, 561
- Ma Y. D., 2011, Int. J. Nanomed., 6, 2679
- 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F · doi:10.1002/(sici)1097-4636(199908)46:2<236::aid-jbm13>3.0.co;2-f
- Krishna R., 2000, Eur. J. Cancer Sci., 11, 265
- Kettiger H., 2013, Int. J. Nanomed., 8, 3255
- Yuan F., 1995, Cancer Res., 55, 3752
- Jain R. K., 1987, Cancer Res., 47, 3039
- 10.1021/nn900002m · DOI · Paper page
- Chidambaram M., 2012, Int. J. Pharm. Sci., 2, 117
- 10.1039/C1CS15237H · DOI · Paper page
- 10.1038/nnano.2007.223 · DOI · Paper page
- Mohanraj V. J., 2006, Trop. J. Pharm. Res., 5, 561
- Hong R. L., 1999, Clin. Cancer Res., 5, 3645
- Shamsipour F., 2009, Avicenna J. Med. Biotechnol., 1, 27
- Park J. W., 2002, Clin. Cancer Res., 8, 1172
- Uppada S. B., 2014, Int. J. Nanomed., 9, 43
- Bangham A. D., 1965, J. Mol. Biol., 13, 227
- Mueller C., 1994, Methods Cell Sci., 16, 183
- 10.1016/j.cbpa.2005.10.005 · DOI
Cited by
Items 701–800 of 1,005
Zhang, Z., Liu, C., Li, C., Wu, W., & Jiang, X. (2019) · Research · doi:10.34133/2019/2391486 · Cited by 52
“To overcome these obstacles, we need to understand definitely the effects of the physicochemical properties of nanomaterials on their biological properties and design more efficient drug delivery systems [2, 14, 15].”
BackgroundLi, L., Lu, Y., Lin, Z., Mao, A. S., Jiao, J., Zhu, Y., Jiang, C., Yang, Z., Peng, M., & Mao, C. (2019) · Materials Horizons · doi:10.1039/c9mh00014c · Cited by 44
Kumar, G., Kant, A., Kumar, M., & Masram, D. T. (2019) · Inorganica Chimica Acta · doi:10.1016/j.ica.2019.119036 · Cited by 44
Luo, X., Zhang, J., Wu, Y., Yang, X., Kuang, X., Li, W., Li, Y., He, R., & Liu, M. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01709 · Cited by 44
Nanobottles for Controlled Release and Drug Delivery
Qiu, J., Xu, J., & Younan Xia, A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000587 · Cited by 44
Zhang, B., Chen, X., Fan, X., Zhu, J., Wei, Y., Zheng, H., Zheng, H., Wang, B., Piao, J., & Li, F. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00648-x · Cited by 48
“due to their tunable size at the nanoscale, ability to envelop both hydrophilic and hydrophilic agents, ease of functionality, and passive targeting through the enhanced permeability and retention (EPR) effect [29].”
BackgroundBiodegradable Passion Fruit-Like Nano-Architectures as Carriers for Cisplatin Prodrug
Cassano, D., Santi, M., Cappello, V., Luin, S., Signore, G., & Voliani, V. (2016) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201600175 · Cited by 43
Sachdeva, V., Monga, A., Vashisht, R., Singh, D., Singh, A., & Bedi, N. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103585 · Cited by 47
Devi, L. S., Casadidio, C., Gigliobianco, M. R., Martino, P. D., & Censi, R. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123976 · Cited by 46
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
Liu, N., Wang, X., Wang, Z., Yonemori, K., Fang, Y., Gao, J., Kong, X., & Wang, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01692-4 · Cited by 55
“Their unique properties, including enhanced permeability, retention, and controlled drug release, enable precise localization at the tumor site; this minimizes off-target effects while maximizing immunostimulatory potential [78, 79].”
Witzler, M., Küllmer, F., Hirtz, A., & Günther, K. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b01248 · Cited by 50
Dong, X., Yin, W., Yu, J., Dou, R., Bao, T., Zhang, X., Yan, L., Yong, Y., Su, C., Wang, Q., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600287 · Cited by 43
Lee, J., Saw, P. E., Gujrati, V., Lee, Y., Kim, H., Kang, S., Choi, M., Kim, J.-I., & Jon, S. (2015) · Theranostics · doi:10.7150/thno.13657 · Cited by 43
“livery platforms for therapeutic siRNA in hepatic diseases,[12-14] as these nanoparticles tend to preferentially localize to the liver upon systemic administration.[15-17] In contrast, the systemic delivery of siRNA to treat solid tumors has proven more difficult.”
BackgroundCodelivery of Anticancer Drugs and siRNA By Mesoporous Silica Nanoparticles
Hanafi‐Bojd, M. Y., Ansari, L., & Malaekeh‐Nikouei, B. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0045 · Cited by 47
Cheng, X., Jin, Y. P., Qi, R., Fan, W., Li, H., Sun, X., & Lai, S. (2016) · Polymer · doi:10.1016/j.polymer.2016.08.087 · Cited by 43
Water‐Soluble, Thermostable, Photomodulated Color‐Switching Quantum Dots
Dı́az, S. A., Gillanders, F., Susumu, K., Oh, E., Medintz, I. L., & Jovin, T. M. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604688 · Cited by 43
Glyco-decorated tobacco mosaic virus as a vector for cisplatin delivery
Liu, X., Liu, B., Gao, S., Wang, Z., Tian, Y., Wu, M., Jiang, S., & Niu, Z. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00100b · Cited by 46
John, J. V., Uthaman, S., Augustine, R., Chen, H., Park, I., & Kim, I. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00030h · Cited by 43
Wang, L., Huo, M., Chen, Y., & Shi, J. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700720 · Cited by 43
Recent progress on mitochondrial targeted cancer therapy based on inorganic nanomaterials
Xu, Z., Chen, X., Sun, Z., Li, C., & Jiang, B. (2019) · Materials Today Chemistry · doi:10.1016/j.mtchem.2019.02.004 · Cited by 43
An, P., Gu, D., Gao, Z., Fan, F., Jiang, Y. D., & Sun, B. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02268f · Cited by 43
Yu, Q., Zhou, J., Song, J., Zhou, H., Kang, B., Chen, H., & Xu, J. (2022) · Small · doi:10.1002/smll.202206592 · Cited by 45
Uslu, D., Abas, B. İ., Demirbolat, G. M., & Çevik, Ö. D. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10591-6 · Cited by 46
Impact of the amount of PEG on prodrug nanoassemblies for efficient cancer therapy
Li, Y., Li, L., Jin, Q., Liu, T., Sun, J., Wang, Y., Yang, Z., He, Z., & Sun, B. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.002 · Cited by 57
Immunomodulatory role of metalloproteases in cancers: Current progress and future trends
Wang, Q., Wang, K., Tan, X., Li, Z., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1064033 · Cited by 49
Magnetic silica nanocomposites for magnetic hyperthermia applications
Ansari, L., & Malaekeh‐Nikouei, B. (2016) · International Journal of Hyperthermia · doi:10.1080/02656736.2016.1243736 · Cited by 43
“Insufficiently, drug delivery to cancer cells besides adverse effects on the other tissues are examples of these limitations that cause the high-cancer mortality [1].”
BackgroundAnalytical techniques and methods for study of drug-lipid membrane interactions
Li, H., Zhao, T., & Sun, Z. (2017) · Reviews in Analytical Chemistry · doi:10.1515/revac-2017-0012 · Cited by 44
“Examples can also be found in targeting delivery of anticancer drugs (Bareford & Swaan, 2007; Sun et al., 2014).”
BackgroundHeparin‐Mimicking Sulfonated Polymer Nanoparticles via RAFT Polymerization‐Induced Self‐Assembly
Gurnani, P., Bray, C., Richardson, R. A. E., Peltier, R., & Perrier, S. (2018) · Macromolecular Rapid Communications · doi:10.1002/marc.201800314 · Cited by 42
Chen, R., Wulff, J. E., & Moffitt, M. G. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00529 · Cited by 44
Redox Responsive Polymersomes for Enhanced Doxorubicin Delivery
Nehate, C., Nayal, A., & Koul, V. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00238 · Cited by 43
Advances of Nanoparticles for Leukemia Treatment
Shen, J., Lü, Z., Wang, J., Zhang, T., Yang, H. J., Li, Y., Liu, G., & Zhang, X. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01040 · Cited by 43
Zhang, Z., Lu, Z., Yuan, Q., Zhang, C., & Tang, Y. (2021) · Journal of Materials Chemistry B · doi:10.1039/d0tb02996c · Cited by 42
Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics
Jindal, A., Sarkar, S., & Alam, A. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.629635 · Cited by 43
Lu, C., & Yeh, Y. (2021) · Small · doi:10.1002/smll.202105997 · Cited by 43
Sivamaruthi, B. S., Thangaleela, S., Kesika, P., Suganthy, N., & Chaiyasut, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020439 · Cited by 43
“Breast, ovarian, and lung cancers have been treated with NPs [21].”
BackgroundLuteolin-Loaded Nanoparticles for the Treatment of Melanoma
Fu, Q.-T., Zhong, X., Chen, M., Gu, J., Zhao, J., Chen, Y., & Tan, F. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s400329 · Cited by 41
“Drug-carrying NPs have been shown to prolong the circulation time of small molecule drugs and to passively target tumor sites due to their enhanced permeability and retention effect (EPR).(25) Reactive oxygen species (ROS) are closely related to the occurrence and development of cancer.”
BackgroundNanotechnology improves the detection of bacteria: Recent advances and future perspectives
Takallu, S., Aiyelabegan, H. T., Zomorodi, A. R., Khotina, V. A., Aflakian, F., Asvar, Z., Moradi, F., behbahani, M. R., Mirzaei, E., Sarhadi, F., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32020 · Cited by 42
“The fast advancement of nanotechnology in recent years has given rise to fresh optimism for the use of nanomaterials in the biomedical sector [7].”
BackgroundElci, S. G., Yan, B., Kim, S. T., Saha, K., Jiang, Y. Y., Klemmer, G. A., Moyano, D. F., Tonga, G. Y., Rotello, V. M., & Vachet, R. W. (2016) · The Analyst · doi:10.1039/c6an00123h · Cited by 41
Glutathione-responsive paclitaxel dimer nanovesicles with high drug content
Pei, Q., Hu, X., Zhou, J., Liu, S., & Xie, Z. (2017) · Biomaterials Science · doi:10.1039/c7bm00052a · Cited by 43
Controlling Structure and Function of Polymeric Drug Delivery Nanoparticles Using Microfluidics
Bains, A., Cao, Y., Kly, S., Wulff, J. E., & Moffitt, M. G. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00177 · Cited by 43
Witzler, M., Küllmer, F., & Günther, K. (2017) · Analytical Letters · doi:10.1080/00032719.2017.1327538 · Cited by 44
“In clinical studies for cancer therapy, gold nanoparticles (AuNP) are used for drug targeting (Lin et al. 2009; Sun et al. 2014) or immunoassays (Hirsch et al.”
BackgroundCharged Metallopolymer-Grafted Silica Nanoparticles for Antimicrobial Applications
Pageni, P., Yang, P., Chen, Y. P., Huang, Y., Bam, M., Zhu, T., Nagarkatti, M., Benicewicz, B. C., Decho, A. W., & Tang, C. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.7b01510 · Cited by 43
Yim, G., Kang, S., Kim, Y., Kim, Y., Min, D., & Jang, H. (2019) · ACS Nano · doi:10.1021/acsnano.8b09516 · Cited by 41
Loiseau, A., Boudon, J., Oudot, A., Moreau, M., Boidot, R., Chassagnon, R., Saïd, N. M., Roux, S., Mirjolet, C., & Millot, N. (2019) · Cancers · doi:10.3390/cancers11121962 · Cited by 42
“The functionalization of nanocarrier-TiONts is mandatory in order to have new or complementary functionalities such as stability and biocompatibility in physiological conditions for biomedical applications [19,40,43,47].”
BackgroundMartínez‐Carmona, M., Ho, Q. P., Morand, J., García, A., Ortega, E., Erthal, L. C. S., Ruiz‐Hernández, E., Santana, M. D., Ruiz, J., Vallet‐Regí, M., et al. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c01436 · Cited by 44
Madkhali, O. A. A., Moni, S. S., Sultan, M. H., Bukhary, H. A., Ghazwani, M., Alhakamy, N. A., Meraya, A. M., Alshahrani, S., Alqahtani, S. S., Bakkari, M. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89330-0 · Cited by 41
Applications of Aptamer-Bound Nanomaterials in Cancer Therapy
Zhu, L., Zhao, J., Guo, Z., Liu, Y., Chen, H., Zhu, C., & He, N. (2021) · Biosensors · doi:10.3390/bios11090344 · Cited by 43
Wang, Y., Wang, Q., Wang, X., Yao, P., Dai, Q., Qi, X., Yang, M., Zhang, X., Huang, R., Yang, J. L., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02013-y · Cited by 40
Self-citationEmerging Biomimetic Drug Delivery Nanoparticles Inspired by Extracellular Vesicles
Sundaram, V., & Aryal, S. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70025 · Cited by 54
“The advantage of utilizing nanomaterials as drug delivery systems (DDS) resides in their nano size, allowing them to pass through biological barriers and constricted capillaries, ultimately reaching specific organs, tumors, or individual cells (Sun et al. 2014).”
Wei, X. X., Jiang, Y., Chenwu, F., Li, Z., Wan, J., Li, Z., Zhang, L., Wang, J., & Song, M. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01862-6 · Cited by 62
Uzakova, A., Yergaliyeva, E. M., Yerlanuly, A., & Mukatayeva, Z. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics18010011 · Cited by 57
“Although the enhanced permeability and retention (EPR) effect promotes tumor accumulation [5], its heterogeneity limits reliability [6,7].”
Rahmani, S., Villa, C. H., Dishman, A. F., Waselewski, M. E., Pan, D. C., Durmaz, H., Misra, A. C., Colón-Meléndez, L., Solomon, M. J., Muzykantov, V. R., et al. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1076428 · Cited by 39
Design strategy of surface decoration for efficient delivery of nanoparticles by computer simulation
Ding, H., & Ma, Y. (2016) · Scientific Reports · doi:10.1038/srep26783 · Cited by 48
Synthesis and biological evaluation of PEGylated CuO nanoparticles
Giannousi, K., Hatzivassiliou, E., Mourdikoudis, S., Vourlias, G., Pantazaki, Α. A., & Dendrinou-Samara, C. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.09.003 · Cited by 40
Functionalization of nanoparticles in specific targeting and mechanism release
Adamo, G., Campora, S., & Ghersi, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46142-9.00003-7 · Cited by 43
Tawiah, K. D., Porciani, D., & Burke, D. H. (2017) · Biomedicines · doi:10.3390/biomedicines5030051 · Cited by 41
“Though significant advances have been made in the fundamental understanding of cancer biology, the treatment of some cancer forms remains elusive, and many cancer treatments suffer from severe side effects [1,2].”
BackgroundSolubility Improvement of Benexate through Salt Formation Using Artificial Sweetener
Putra, O. D., Umeda, D., Fujita, E., Haraguchi, T., Uchida, T., Yonemochi, E., & Uekusa, H. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020064 · Cited by 40
“However, some concerns regarding the safety of this technique have been addressed recently [11,12].”
BackgroundWu, X., Liu, J. L., Yang, L., & Wang, F. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.11.088 · Cited by 40
Trushina, D. B., Akasov, R., Khovankina, A. V., Borodina, T. N., Букреева, Т. В., & Арнольдовна, М. Е. (2019) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2019.03.152 · Cited by 48
Zhang, Y., Zhang, L., Lin, X., Ke, L., Li, B., Xu, L., Lv, T., Li, Z., Chen, H., & Gao, Y. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.04.140 · Cited by 40
Self-citationSurface engineering and applications of nanodiamonds in cancer treatment and imaging
Lai, H., Stenzel, M. H., & Xiao, P. (2019) · International Materials Reviews · doi:10.1080/09506608.2019.1622202 · Cited by 41
“tance acquired by cancer cells after treatment, leading to relapse, also accounts for some of the failures [2,3].”
BackgroundZhang, M., Yang, C., Yan, X., Sung, J. J., Garg, P., & Merlin, D. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900129 · Cited by 50
Verma, G., Shetake, N. G., Pandrekar, S., Pandey, B. N., Hassan, P. A., & Priyadarsini, K. I. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105206 · Cited by 40
Li, Q., Fu, D., Zhang, J., Yan, H. X., Wang, H., Niu, B., Guo, R., & Liu, Y. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111586 · Cited by 40
Non-origami DNA for functional nanostructures: From structural control to advanced applications
Zhang, L. H., Ma, X., Wang, G., Liang, X., Mitomo, H., Pike, A. R., Houlton, A., & Ijiro, K. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101154 · Cited by 41
Gao, F., Sun, Z., Zhao, L., Chen, F., Stenzel, M. H., Wang, F., Li, H., Zhang, L., & Jiang, Y. (2021) · Materials Chemistry Frontiers · doi:10.1039/d1qm00402f · Cited by 41
Xu, Z., Ni, K., Mao, J., Luo, T., & Lin, W. (2021) · Advanced Materials · doi:10.1002/adma.202104249 · Cited by 41
Facile Generation of Tumor‐pH‐Labile Linkage‐Bridged Block Copolymers for Chemotherapeutic Delivery
Sun, C., Liu, Y., Du, J., Cao, Z., Xu, C., & Wang, J. (2015) · Angewandte Chemie · doi:10.1002/ange.201509507 · Cited by 41
Antoniraj, M. G., Kumar, C. S., & Kandasamy, R. (2015) · Colloid & Polymer Science · doi:10.1007/s00396-015-3804-4 · Cited by 40
Doxorubicin-loaded, pH-sensitive Albumin Nanoparticles for Lung Cancer Cell Targeting
Aziz, A. N., Sefidbakht, Y., Rezaei, S., Kouchakzadeh, H., & Uskoković, V. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.12.006 · Cited by 39
Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations
Tuguntaev, R. G., Hussain, A., Fu, C., Chen, H., Tao, Y., Huang, Y. H., Liu, L., Liang, X., & Guo, W. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01451-4 · Cited by 43
Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance
Lin, G., Wang, J., Yang, Y., Zhang, Y., & Sun, T. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1242126 · Cited by 43
Self-citationCovalent organic frameworks (COFs) as carrier for improved drug delivery and biosensing applications
Younas, R., Jubeen, F., Bano, N., Andreescu, S., Hong-xia, Z., & Hayat, A. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28718 · Cited by 43
John, J. V., Uthaman, S., Augustine, R., Manickavasagam Lekshmi, K., Park, I., & Kim, I. (2017) · Journal of Polymer Science Part A: Polymer Chemistry · doi:10.1002/pola.28602 · Cited by 39
Lojk, J., Bregar, V. B., Strojan, K., Hudoklin, S., Veranič, P., Pavlin, M., & Kreft, M. E. (2017) · Histochemistry and Cell Biology · doi:10.1007/s00418-017-1605-1 · Cited by 39
Hussain, M., Raja, N. I., Mashwani, Z., Naz, F., Iqbal, M., & Aslam, S. (2018) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2017.0153 · Cited by 39
Li, W., Peng, J., Yang, Q., Chen, L., Zhang, L. H., Chen, X., & Qian, Z. (2018) · Biomaterials Science · doi:10.1039/c8bm00096d · Cited by 39
Iglesias, N., Galbis, E., Valencia, C., de‐Paz, M. ‐., & Galbis, J. A. (2018) · Polymers · doi:10.3390/polym10040392 · Cited by 39
Li, X., Zhao, H., Yu, J. H., Yin, C., Li, J., Yáng, Z., Tang, Y., Zhang, Q., Fan, Q., & Huang, W. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b16818 · Cited by 39
Sheavly, J. K., Pedersen, J. A., & Lehn, R. C. V. (2019) · Nanoscale · doi:10.1039/c8nr07763k · Cited by 41
Suarasan, S., Craciun, A.-M., Licărete, E., Focşan, M., Magyari, K., & Aştilean, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b21269 · Cited by 39
Translocation Mechanisms of Cell-Penetrating Polymers Identified by Induced Proton Dynamics
Goda, T., Imaizumi, Y., Hatano, H., Matsumoto, A., Ishihara, K., & Miyahara, Y. (2019) · Langmuir · doi:10.1021/acs.langmuir.9b00856 · Cited by 40
Biomedical Applications of Hyaluronic Acid-Based Nanomaterials in Hyperthermic Cancer Therapy
Kim, S., Moon, M. J., Surendran, S. P., & Jeong, Y. Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070306 · Cited by 41
“To distribute a drug into a tumor site while avoiding other organs, it is necessary to design specifically engineered nanoparticles by modifying the surface with targeting moieties [4,5].”
BackgroundZhang, T., Liu, H., Li, Y., Li, C., Wan, G., Chen, B., Li, C., & Wang, Y. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.001 · Cited by 40
“Nanocarriers can increase drug solubility, improve drug stability and bioavailability, minimize drug toxic side effects, and deliver drug molecules specifically to tumors through the enhanced permeability and retention (EPR) effect and/or the active tumor-targeting effect [17,18].”
BackgroundIn Situ Ligand-Directed Growth of Gold Nanoparticles in Biological Tissues
Peng, C., Yu, M., & Zheng, J. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b04911 · Cited by 40
Coordination-based self-assembled capsules (SACs) for protein, CRISPR–Cas9, DNA and RNA delivery
Alimi, L. O., Alyami, M., Chand, S., Baslyman, W. S., & Khashab, N. M. (2021) · Chemical Science · doi:10.1039/d0sc05975g · Cited by 39
Mignani, S. M., Shi, X., Ceña, V., Rodrigues, J., Tomás, H., & Majoral, J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.003 · Cited by 41
Xu, X., Zhang, R., Yang, X., Lu, Y., Yang, Z., Peng, M., Ma, Z., Jiao, J., & Li, L. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100518 · Cited by 40
Deng, K., Chen, Y., Li, C., Deng, X., Hou, Z., Cheng, Z., Han, Y., Xing, B., & Lin, J. (2017) · Journal of Materials Chemistry B · doi:10.1039/c6tb03233h · Cited by 40
Chen, M., Wang, Y., Yuan, P., Wang, L., Li, X., & Lei, B. (2024) · Regenerative Biomaterials · doi:10.1093/rb/rbae110 · Cited by 44
Bio-nanomaterials: Promising anticancer properties and treatment strategies
Elemike, E. E., Onunkwo, I. C., Ughumiakpor, O., Alawuru, F., Mukoro, A., Ishom, P., Obarakpor, F., Hossain, I., & Aziza, A. E. (2025) · Nano TransMed · doi:10.1016/j.ntm.2025.100076 · Cited by 44
A dextran–platinum( iv ) conjugate as a reduction-responsive carrier for triggered drug release
He, S., Cong, Y., Zhou, D., Li, J., Xie, Z., Chen, X., Jing, X., & Huang, Y. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01496d · Cited by 39
Su, C., Tsai, C., Tomanek, B., Chen, W., & Cheng, F. (2016) · Nanoscale · doi:10.1039/c6nr00280c · Cited by 38
Wu, X., Zhou, L., Su, Y., & Dong, C. (2016) · Polymer Chemistry · doi:10.1039/c6py01189f · Cited by 38
Li, X., Liu, Y., Wu, X., Gao, Y., Zhang, J., Zhang, D., Gu, S., Zhu, G., & Liu, G. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s108128 · Cited by 41
“A large number of aptamer-mediated nanocarriers have been developed for targeted cancer therapy because not only can they enhance water solubility and bioavailability, but they also have inherent properties of high specificity and affinity.(21,22) Polyethylene glycol (PEG)-modified NPs have been used as a stable vehic…”
Passion fruit-like nano-architectures: a general synthesis route
Cassano, D., David, J., Luin, S., & Voliani, V. (2017) · Scientific Reports · doi:10.1038/srep43795 · Cited by 38
Recent Advances in Self-assembled Nano-therapeutics
Zheng, C., Zhao, Y., & Liu, Y. (2017) · Chinese Journal of Polymer Science · doi:10.1007/s10118-018-2078-y · Cited by 39
Size-controllable dual drug-loaded silk fibroin nanospheres through a facile formation process
Wu, M., Yang, W., Chen, S., Yao, J., Shao, Z., & Chen, X. (2018) · Journal of Materials Chemistry B · doi:10.1039/c7tb03113k · Cited by 38
An eco-friendly process for zerovalent bismuth nanoparticles synthesis
Reverberi, A. P., Varbanov, P. S., Lauciello, S., Salerno, M., & Fabiano, B. (2018) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2018.07.011 · Cited by 38
Silk fibroin nanoparticles for enhanced bio-macromolecule delivery to the retina
Yang, P., Dong, Y., Huang, D., Zhu, C., Liu, H., Pan, X., & Wu, C. (2018) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2018.1545236 · Cited by 39
“Nanoparticles as drug carriers have a variety of advantages, including enhanced drug bioavailability, sustained drug release, and reduced toxicity (Sun et al. 2014).”
Background
Metadata
- Authors
- Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y.
- Affiliations
- Georgia Institute of Technology (US)
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2014-10-07
- Volume
- 53
- Issue
- 46
- Pages
- 12320-12364
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2134726513
- Cited by
- 2,164
- References
- 578
- Citations by year
- 2026: 57 · 2025: 146 · 2024: 163 · 2023: 153 · 2022: 209 · 2021: 200 · 2020: 221 · 2019: 237 · 2018: 257 · 2017: 230 · 2016: 180 · 2015: 109 · 2014: 2
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- engineered nanoparticles, drug delivery, cancer therapy, targeted drug delivery, enhanced permeability and retention effect, pH-responsive delivery, tumor-targeting ligands, tissue distribution, circulation half-life, immunogenicity, combination therapy, multidrug resistance, contrast media, theranostics, nanoparticle surface modification
- MeSH terms
- Animals, Antineoplastic Agents, Delayed-Action Preparations, Humans, Neoplasms, Drug Delivery Systems, Nanotechnology, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.